Global Pediatric Vaccines Market By Type (Monovalent, Multivalent), By Technology (Live Attenuated Vaccines, Inactivated Vaccines, Toxoid Vaccines, Subunit, Recombinant, Polysaccharide, and Conjugate Vaccines), By Indication (Varicella, Diphtheria, Pertussis and Tetanus, Influenza, Human Papilloma Virus, Measles, Mumps and Rubella, Meningococcal Disease, Pneumococcal Disease, Polio, Rotavirus, Other Indications): Global Opportunity Analysis and Industry Forecast, 2021-2031

Pediatric Vaccines Market

The pediatric vaccines market is likely to experience a significant growth rate of 5.4% from 2022-2031 owing to increasing market demand for pediatric vaccine product from healthcare sector –

Pediatric vaccines are the vaccines given to the children as a kind of protection against dangerous, frequently fatal infections. Pediatric vaccines stimulate a child's immune response to a particular disease, which helps the child's immune system fight infections more effectively. Pediatric vaccines include pneumococcal vaccine, DTP vaccine, rotavirus vaccine, MMR vaccine, polio vaccine, influenza vaccine, hepatitis B vaccine, Hib vaccine, and meningococcal vaccine. Before becoming available to the general public, all vaccinations must pass stringent safety evaluations, including clinical trials. Only vaccinations that pass strict quality and safety requirements will be registered and distributed by nations.

Major factors driving the growth of the pediatric vaccines market include increase in focus on improving primary healthcare, increase in investment of government as well as non-government organization and increasing the accessibility of vaccines by making them available at affordable rates at government institutions. In addition, surge in immunization program across the globe drive the growth of the market. For instance, MenA vaccine has been approved and implemented in almost 22 countries and is a part of routine immunization in 8 countries of the meningitis belt. According to CDC, the Food and Drug Administration (FDA) licensed 11 vaccines for use in the U.S. to help protect against diphtheria and tetanus. Moreover, increase in R&D activities to develop new vaccine further boost the market growth. For instance, GSK has increased investments in R&D and new products to deliver future growth. In addition, Sanofi received an approval in April, 2020 for Meningococcal ACYW Conjugate vaccine.

Moreover, in June, 2021, Merck and Sanofi received an approval for six-in-one pediatric combination vaccine in the U.S. However, the high cost of vaccine refrigeration and lack of accessibility to pediatric medications in emerging nations due to inadequate healthcare infrastructure and less awareness are the factors which is anticipated to impede market expansion. Conversely, increase in childbirths associated with high risk of infection due to poor infant immunity, high risk of meningitis, measles, rotavirus, pneumococcal disease, and growth in awareness toward immunization are some of the factors that provide lucrative opportunities for the vaccines across the emerging markets. Moreover, the market also offers growth opportunities to the key players in the market. As the development of new vaccines to treat pediatric disorder, there is an estimated a rise in demand for the pediatric vaccine products during the forecast period. 

The global pediatric vaccines market is segmented on the basis of type, technology, indication, and region. As per type, the market is categorized into monovalent and multivalent. On the basis of technology, it is bifurcated into live attenuated vaccines, inactivated vaccines, toxoid vaccines, and subunit, recombinant, polysaccharide, and conjugate vaccines.  On the basis of indication, it is segmented into varicella, diphtheria, pertussis & tetanus, influenza, human papilloma virus, measles, mumps & rubella, meningococcal disease, pneumococcal disease, polio, rotavirus, and others. Region wise, it is analyzed across North America (the U.S., Canada, and Mexico), Europe (the UK, Germany, France, Italy, Spain, and rest of Europe), Asia-Pacific (China, India, Japan, Australia, South Korea and Rest of Asia-Pacific), and LAMEA (Brazil, Saudi Arabia, South Africa, and Rest of LAMEA).

The key players profiled in the study includes the Serum Institute of India Pvt. Ltd., Pfizer, Johnson & Johnson, AstraZeneca plc. GlaxoSmithKline plc., Sanofi Aventis, Merck & Co., Inc., Emergent BioSolutions Inc., CSL Limited, and Novavax, Inc. The players in the market have been actively engaged in the adoption strategy such as product approval, acquisition, product launch and collaboration to remain competitive and gain advantage over the competitors in the market. For instance, In October 2021, Johnson & Johnson announced the U.S. Food and Drug Administration (FDA) have issued Emergency Use Authorization (EUA) for a booster dose of the Johnson & Johnson COVID-19 vaccine for adults aged 18 and older. In addition, In June 2022, Merck announced that the U.S. Food and Drug Administration (FDA) has approved VAXNEUVANCE (Pneumococcal 15-valent Conjugate Vaccine) for the Prevention of Invasive Pneumococcal Disease in Infants and Children.

Key Market Insights (Updated)

• By type, the monovalent segment was the highest revenue contributor to the market with a CAGR of 5.0% during the forecast period and is estimated to reach $ 28,297.2 million by 2031.

• Based on technology, the subunit, recombinant, polysaccharide, and conjugate vaccines segment dominates the market in 2021, and is expected to continue this trend during the forecast period.

• Based on indication, the pneumococcal segment dominates the market in 2021, and is expected to continue this trend during the forecast period.

• Based on region, North America garnered the largest revenue share in 2021, whereas Asia-Pacific is anticipated to grow at the highest CAGR of 6.9% during the forecast period

 

Overview

The global pediatric vaccine market accounted for $2,1371.73 million in 2021, and is expected to reach $ 3,6390.99 million by 2031, registering a CAGR of 5.4% from 2022 to 2031.

Pediatric vaccine is a biological preparation that is administered to produce acquired immunity in children. Administration of vaccines aids to enhance immune response against a specific pathogen. Pediatric vaccinations play a key role in sustaining children health across different countries; hence, they are used in various national disease-prevention strategies. Owing to the increased occurrence of both viral and bacterial infectious diseases, the demand for vaccines has grown over the past few years. Pediatric vaccinations are primarily provided to children of different ages, improving their immune system during their lives and ensuring defense against various forms of infectious diseases.

It is estimated that pediatric vaccine market is expected to experience significant market growth during the forecast period as there has been surge in adoption in several countries across the globe in the national immunization programs. In addition, rise in prevalence of pneumococcal, influenza, and meningococcal disease in several countries has led to upsurge in demand for vaccines, which further facilitate the growth of the market. However, stringent government regulations for the approval of new vaccines and recall of several products are expected to impede the market growth. In contrast, rise in demand in emerging markets, increase in R&D activities to develop new vaccines, and surge in healthcare spending are anticipated to provide significant growth opportunities for the pediatric vaccine market.

The pediatric vaccine market is segmented on the basis of type, technology, indication, and region. On the basis of type, the market is bifurcated into monovalent and multivalent. Depending on technology, it is classified into live attenuated vaccines, inactivated vaccines, toxoid vaccines, and subunit, recombinant, polysaccharide, and conjugate vaccines. By indication, it is classified into varicella, diphtheria, pertussis & tetanus, influenza, human papilloma virus, measles, mumps & rubella, meningococcal disease, pneumococcal disease, polio, rotavirus, and others.

Region wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).

The report provides a comprehensive analysis of the key players that operate in the global pediatric vaccine market. Key companies profiled in the report include Serum Institute of India Pvt. Ltd., Pfizer, Johnson & Johnson, AstraZeneca plc. GlaxoSmithKline plc., Sanofi Aventis, Merck & Co., Inc., Emergent BioSolutions Inc., CSL Limited, and Novavax, Inc.

Key Benefits For Stakeholders

●This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the global paediatric vaccine market analysis from 2021 to 2031 to identify the prevailing global paediatric vaccine market opportunities.

●The market research is offered along with information related to key drivers, restraints, and opportunities.

●Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.

●In-depth analysis of the global paediatric vaccine market segmentation assists to determine the prevailing market opportunities.

●Major countries in each region are mapped according to their revenue contribution to the global market.

●Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.

●The report includes the analysis of the regional as well as global global paediatric vaccine market trends, key players, market segments, application areas, and market growth strategies.

Key Market Segments

○ Serum Institute of India Pvt. Ltd

Scope of Pediatric Vaccines Market Report

1.1.Report description

1.2.Key market segments

1.3.Key benefits to the stakeholders

1.4.Research Methodology

1.4.1.Secondary research

1.4.2.Primary research

1.4.3.Analyst tools and models

2.1.Key findings of the study

2.2.CXO Perspective

3.1.Market definition and scope

3.2.Key findings

3.2.1.Top investment pockets

3.3.Porter’s five forces analysis

3.4.Top player positioning

3.5.Market dynamics

3.5.1.Drivers

3.5.2.Restraints

3.5.3.Opportunities

3.6.COVID-19 Impact Analysis on the market

4.1 Overview

4.1.1 Market size and forecast

4.2 Monovalent

4.2.1 Key market trends, growth factors and opportunities

4.2.2 Market size and forecast, by region

4.2.3 Market share analysis by country

4.3 Multivalent

4.3.1 Key market trends, growth factors and opportunities

4.3.2 Market size and forecast, by region

4.3.3 Market share analysis by country

5.1 Overview

5.1.1 Market size and forecast

5.2 Live Attenuated Vaccines

5.2.1 Key market trends, growth factors and opportunities

5.2.2 Market size and forecast, by region

5.2.3 Market share analysis by country

5.3 Inactivated Vaccines

5.3.1 Key market trends, growth factors and opportunities

5.3.2 Market size and forecast, by region

5.3.3 Market share analysis by country

5.4 Toxoid Vaccines

5.4.1 Key market trends, growth factors and opportunities

5.4.2 Market size and forecast, by region

5.4.3 Market share analysis by country

5.5 Subunit, Recombinant, Polysaccharide, and Conjugate Vaccines

5.5.1 Key market trends, growth factors and opportunities

5.5.2 Market size and forecast, by region

5.5.3 Market share analysis by country

6.1 Overview

6.1.1 Market size and forecast

6.2 Varicella

6.2.1 Key market trends, growth factors and opportunities

6.2.2 Market size and forecast, by region

6.2.3 Market share analysis by country

6.3 Diphtheria, Pertussis and Tetanus

6.3.1 Key market trends, growth factors and opportunities

6.3.2 Market size and forecast, by region

6.3.3 Market share analysis by country

6.4 Influenza

6.4.1 Key market trends, growth factors and opportunities

6.4.2 Market size and forecast, by region

6.4.3 Market share analysis by country

6.5 Human Papilloma Virus

6.5.1 Key market trends, growth factors and opportunities

6.5.2 Market size and forecast, by region

6.5.3 Market share analysis by country

6.6 Measles, Mumps and Rubella

6.6.1 Key market trends, growth factors and opportunities

6.6.2 Market size and forecast, by region

6.6.3 Market share analysis by country

6.7 Meningococcal Disease

6.7.1 Key market trends, growth factors and opportunities

6.7.2 Market size and forecast, by region

6.7.3 Market share analysis by country

6.8 Pneumococcal Disease

6.8.1 Key market trends, growth factors and opportunities

6.8.2 Market size and forecast, by region

6.8.3 Market share analysis by country

6.9 Polio

6.9.1 Key market trends, growth factors and opportunities

6.9.2 Market size and forecast, by region

6.9.3 Market share analysis by country

7.0 Rotavirus

7.0.1 Key market trends, growth factors and opportunities

7.0.2 Market size and forecast, by region

7.0.3 Market share analysis by country

7.1 Other Indications

7.1.1 Key market trends, growth factors and opportunities

7.1.2 Market size and forecast, by region

7.1.3 Market share analysis by country

7.1 Overview

7.1.1 Market size and forecast

7.2 North America

7.2.1 Key trends and opportunities

7.2.2 North America Market size and forecast, by Type

7.2.3 North America Market size and forecast, by Technology

7.2.4 North America Market size and forecast, by Indication

7.2.5 North America Market size and forecast, by country

7.2.5.1 U.S.

7.2.5.1.1 Key market trends, growth factors and opportunities

7.2.5.1.2 Market size and forecast, by Type

7.2.5.1.3 Market size and forecast, by Technology

7.2.5.1.4 Market size and forecast, by Indication

7.2.5.2 Canada

7.2.5.2.1 Key market trends, growth factors and opportunities

7.2.5.2.2 Market size and forecast, by Type

7.2.5.2.3 Market size and forecast, by Technology

7.2.5.2.4 Market size and forecast, by Indication

7.2.5.3 Mexico

7.2.5.3.1 Key market trends, growth factors and opportunities

7.2.5.3.2 Market size and forecast, by Type

7.2.5.3.3 Market size and forecast, by Technology

7.2.5.3.4 Market size and forecast, by Indication

7.3 Europe

7.3.1 Key trends and opportunities

7.3.2 Europe Market size and forecast, by Type

7.3.3 Europe Market size and forecast, by Technology

7.3.4 Europe Market size and forecast, by Indication

7.3.5 Europe Market size and forecast, by country

7.3.5.1 Germany

7.3.5.1.1 Key market trends, growth factors and opportunities

7.3.5.1.2 Market size and forecast, by Type

7.3.5.1.3 Market size and forecast, by Technology

7.3.5.1.4 Market size and forecast, by Indication

7.3.5.2 France

7.3.5.2.1 Key market trends, growth factors and opportunities

7.3.5.2.2 Market size and forecast, by Type

7.3.5.2.3 Market size and forecast, by Technology

7.3.5.2.4 Market size and forecast, by Indication

7.3.5.3 UK

7.3.5.3.1 Key market trends, growth factors and opportunities

7.3.5.3.2 Market size and forecast, by Type

7.3.5.3.3 Market size and forecast, by Technology

7.3.5.3.4 Market size and forecast, by Indication

7.3.5.4 Italy

7.3.5.4.1 Key market trends, growth factors and opportunities

7.3.5.4.2 Market size and forecast, by Type

7.3.5.4.3 Market size and forecast, by Technology

7.3.5.4.4 Market size and forecast, by Indication

7.3.5.5 Spain

7.3.5.5.1 Key market trends, growth factors and opportunities

7.3.5.5.2 Market size and forecast, by Type

7.3.5.5.3 Market size and forecast, by Technology

7.3.5.5.4 Market size and forecast, by Indication

7.3.5.6 Rest of Europe

7.3.5.6.1 Key market trends, growth factors and opportunities

7.3.5.6.2 Market size and forecast, by Type

7.3.5.6.3 Market size and forecast, by Technology

7.3.5.6.4 Market size and forecast, by Indication

7.4 Asia-Pacific

7.4.1 Key trends and opportunities

7.4.2 Asia-Pacific Market size and forecast, by Type

7.4.3 Asia-Pacific Market size and forecast, by Technology

7.4.4 Asia-Pacific Market size and forecast, by Indication

7.4.5 Asia-Pacific Market size and forecast, by country

7.4.5.1 China

7.4.5.1.1 Key market trends, growth factors and opportunities

7.4.5.1.2 Market size and forecast, by Type

7.4.5.1.3 Market size and forecast, by Technology

7.4.5.1.4 Market size and forecast, by Indication

7.4.5.2 Japan

7.4.5.2.1 Key market trends, growth factors and opportunities

7.4.5.2.2 Market size and forecast, by Type

7.4.5.2.3 Market size and forecast, by Technology

7.4.5.2.4 Market size and forecast, by Indication

7.4.5.3 India

7.4.5.3.1 Key market trends, growth factors and opportunities

7.4.5.3.2 Market size and forecast, by Type

7.4.5.3.3 Market size and forecast, by Technology

7.4.5.3.4 Market size and forecast, by Indication

7.4.5.4 Australia

7.4.5.4.1 Key market trends, growth factors and opportunities

7.4.5.4.2 Market size and forecast, by Type

7.4.5.4.3 Market size and forecast, by Technology

7.4.5.4.4 Market size and forecast, by Indication

7.4.5.5 South Korea

7.4.5.5.1 Key market trends, growth factors and opportunities

7.4.5.5.2 Market size and forecast, by Type

7.4.5.5.3 Market size and forecast, by Technology

7.4.5.5.4 Market size and forecast, by Indication

7.4.5.6 Rest of Asia-Pacific

7.4.5.6.1 Key market trends, growth factors and opportunities

7.4.5.6.2 Market size and forecast, by Type

7.4.5.6.3 Market size and forecast, by Technology

7.4.5.6.4 Market size and forecast, by Indication

7.5 LAMEA

7.5.1 Key trends and opportunities

7.5.2 LAMEA Market size and forecast, by Type

7.5.3 LAMEA Market size and forecast, by Technology

7.5.4 LAMEA Market size and forecast, by Indication

7.5.5 LAMEA Market size and forecast, by country

7.5.5.1 Brazil

7.5.5.1.1 Key market trends, growth factors and opportunities

7.5.5.1.2 Market size and forecast, by Type

7.5.5.1.3 Market size and forecast, by Technology

7.5.5.1.4 Market size and forecast, by Indication

7.5.5.2 Saudi Arabia

7.5.5.2.1 Key market trends, growth factors and opportunities

7.5.5.2.2 Market size and forecast, by Type

7.5.5.2.3 Market size and forecast, by Technology

7.5.5.2.4 Market size and forecast, by Indication

7.5.5.3 South Africa

7.5.5.3.1 Key market trends, growth factors and opportunities

7.5.5.3.2 Market size and forecast, by Type

7.5.5.3.3 Market size and forecast, by Technology

7.5.5.3.4 Market size and forecast, by Indication

7.5.5.4 Rest of LAMEA

7.5.5.4.1 Key market trends, growth factors and opportunities

7.5.5.4.2 Market size and forecast, by Type

7.5.5.4.3 Market size and forecast, by Technology

7.5.5.4.4 Market size and forecast, by Indication

8.1. Introduction

8.2. Top winning strategies

8.3. Product Mapping of Top 10 Player

8.4. Competitive Dashboard

8.5. Competitive Heatmap

8.6. Key developments

9.1 AstraZeneca Plc.

9.1.1 Company overview

9.1.2 Company snapshot

9.1.3 Operating business segments

9.1.4 Product portfolio

9.1.5 Business performance

9.1.6 Key strategic moves and developments

9.2 CSL Limited

9.2.1 Company overview

9.2.2 Company snapshot

9.2.3 Operating business segments

9.2.4 Product portfolio

9.2.5 Business performance

9.2.6 Key strategic moves and developments

9.3 Emergent BioSolutions Inc.

9.3.1 Company overview

9.3.2 Company snapshot

9.3.3 Operating business segments

9.3.4 Product portfolio

9.3.5 Business performance

9.3.6 Key strategic moves and developments

9.4 GlaxoSmithKline plc.

9.4.1 Company overview

9.4.2 Company snapshot

9.4.3 Operating business segments

9.4.4 Product portfolio

9.4.5 Business performance

9.4.6 Key strategic moves and developments

9.5 Johnson & Johnson

9.5.1 Company overview

9.5.2 Company snapshot

9.5.3 Operating business segments

9.5.4 Product portfolio

9.5.5 Business performance

9.5.6 Key strategic moves and developments

9.6 Merck & Co., Inc.

9.6.1 Company overview

9.6.2 Company snapshot

9.6.3 Operating business segments

9.6.4 Product portfolio

9.6.5 Business performance

9.6.6 Key strategic moves and developments

9.7 Novavax, Inc.

9.7.1 Company overview

9.7.2 Company snapshot

9.7.3 Operating business segments

9.7.4 Product portfolio

9.7.5 Business performance

9.7.6 Key strategic moves and developments

9.8 Pfizer Inc.

9.8.1 Company overview

9.8.2 Company snapshot

9.8.3 Operating business segments

9.8.4 Product portfolio

9.8.5 Business performance

9.8.6 Key strategic moves and developments

9.9 Sanofi Aventis

9.9.1 Company overview

9.9.2 Company snapshot

9.9.3 Operating business segments

9.9.4 Product portfolio

9.9.5 Business performance

9.9.6 Key strategic moves and developments

9.10 Serum Institute of India Pvt. Ltd.

9.10.1 Company overview

9.10.2 Company snapshot

9.10.3 Operating business segments

9.10.4 Product portfolio

9.10.5 Business performance

9.10.6 Key strategic moves and development

LIST OF TABLES

TABLE 1. GLOBAL GLOBAL PEDIATRIC VACCINES MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)

TABLE 2. GLOBAL PEDIATRIC VACCINES MARKET FOR MONOVALENT, BY REGION, 2021-2031 (REVENUE, $MILLION)

TABLE 3. GLOBAL PEDIATRIC VACCINES MARKET FOR MONOVALENT, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)

TABLE 4. GLOBAL PEDIATRIC VACCINES MARKET FOR MULTIVALENT, BY REGION, 2021-2031 (REVENUE, $MILLION)

TABLE 5. GLOBAL PEDIATRIC VACCINES MARKET FOR MULTIVALENT, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)

TABLE 6. GLOBAL GLOBAL PEDIATRIC VACCINES MARKET, BY TECHNOLOGY, 2021-2031 (REVENUE, $MILLION)

TABLE 7. GLOBAL PEDIATRIC VACCINES MARKET FOR LIVE ATTENUATED VACCINES, BY REGION, 2021-2031 (REVENUE, $MILLION)

TABLE 8. GLOBAL PEDIATRIC VACCINES MARKET FOR LIVE ATTENUATED VACCINES, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)

TABLE 9. GLOBAL PEDIATRIC VACCINES MARKET FOR INACTIVATED VACCINES, BY REGION, 2021-2031 (REVENUE, $MILLION)

TABLE 10. GLOBAL PEDIATRIC VACCINES MARKET FOR INACTIVATED VACCINES, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)

TABLE 11. GLOBAL PEDIATRIC VACCINES MARKET FOR TOXOID VACCINES, BY REGION, 2021-2031 (REVENUE, $MILLION)

TABLE 12. GLOBAL PEDIATRIC VACCINES MARKET FOR TOXOID VACCINES, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)

TABLE 13. GLOBAL PEDIATRIC VACCINES MARKET FOR SUBUNIT, RECOMBINANT, POLYSACCHARIDE, AND CONJUGATE VACCINES, BY REGION, 2021-2031 (REVENUE, $MILLION)

TABLE 14. GLOBAL PEDIATRIC VACCINES MARKET FOR SUBUNIT, RECOMBINANT, POLYSACCHARIDE, AND CONJUGATE VACCINES, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)

TABLE 15. GLOBAL GLOBAL PEDIATRIC VACCINES MARKET, BY INDICATION, 2021-2031 (REVENUE, $MILLION)

TABLE 16. GLOBAL PEDIATRIC VACCINES MARKET FOR VARICELLA, BY REGION, 2021-2031 (REVENUE, $MILLION)

TABLE 17. GLOBAL PEDIATRIC VACCINES MARKET FOR VARICELLA, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)

TABLE 18. GLOBAL PEDIATRIC VACCINES MARKET FOR DIPHTHERIA, PERTUSSIS AND TETANUS, BY REGION, 2021-2031 (REVENUE, $MILLION)

TABLE 19. GLOBAL PEDIATRIC VACCINES MARKET FOR DIPHTHERIA, PERTUSSIS AND TETANUS, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)

TABLE 20. GLOBAL PEDIATRIC VACCINES MARKET FOR INFLUENZA, BY REGION, 2021-2031 (REVENUE, $MILLION)

TABLE 21. GLOBAL PEDIATRIC VACCINES MARKET FOR INFLUENZA, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)

TABLE 22. GLOBAL PEDIATRIC VACCINES MARKET FOR HUMAN PAPILLOMA VIRUS, BY REGION, 2021-2031 (REVENUE, $MILLION)

TABLE 23. GLOBAL PEDIATRIC VACCINES MARKET FOR HUMAN PAPILLOMA VIRUS, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)

TABLE 24. GLOBAL PEDIATRIC VACCINES MARKET FOR MEASLES, MUMPS AND RUBELLA, BY REGION, 2021-2031 (REVENUE, $MILLION)

TABLE 25. GLOBAL PEDIATRIC VACCINES MARKET FOR MEASLES, MUMPS AND RUBELLA, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)

TABLE 26. GLOBAL PEDIATRIC VACCINES MARKET FOR MENINGOCOCCAL DISEASE, BY REGION, 2021-2031 (REVENUE, $MILLION)

TABLE 27. GLOBAL PEDIATRIC VACCINES MARKET FOR MENINGOCOCCAL DISEASE, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)

TABLE 28. GLOBAL PEDIATRIC VACCINES MARKET FOR PNEUMOCOCCAL DISEASE, BY REGION, 2021-2031 (REVENUE, $MILLION)

TABLE 29. GLOBAL PEDIATRIC VACCINES MARKET FOR PNEUMOCOCCAL DISEASE, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)

TABLE 30. GLOBAL PEDIATRIC VACCINES MARKET FOR POLIO, BY REGION, 2021-2031 (REVENUE, $MILLION)

TABLE 31. GLOBAL PEDIATRIC VACCINES MARKET FOR POLIO, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)

TABLE 32. GLOBAL PEDIATRIC VACCINES MARKET FOR ROTAVIRUS, BY REGION, 2021-2031 (REVENUE, $MILLION)

TABLE 33. GLOBAL PEDIATRIC VACCINES MARKET FOR ROTAVIRUS, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)

TABLE 34. GLOBAL PEDIATRIC VACCINES MARKET FOR OTHER INDICATIONS, BY REGION, 2021-2031 (REVENUE, $MILLION)

TABLE 35. GLOBAL PEDIATRIC VACCINES MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)

TABLE 36. GLOBAL PEDIATRIC VACCINES MARKET, BY REGION, 2021-2031 (REVENUE, $MILLION)

TABLE 37. NORTH AMERICA GLOBAL PEDIATRIC VACCINES MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)

TABLE 38. NORTH AMERICA GLOBAL PEDIATRIC VACCINES MARKET, BY TECHNOLOGY, 2021-2031 (REVENUE, $MILLION)

TABLE 39. NORTH AMERICA GLOBAL PEDIATRIC VACCINES MARKET, BY INDICATION, 2021-2031 (REVENUE, $MILLION)

TABLE 40. NORTH AMERICA GLOBAL PEDIATRIC VACCINES MARKET, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)

TABLE 41. U.S. GLOBAL PEDIATRIC VACCINES MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)

TABLE 42. U.S. GLOBAL PEDIATRIC VACCINES MARKET, BY TECHNOLOGY, 2021-2031 (REVENUE, $MILLION)

TABLE 43. U.S. GLOBAL PEDIATRIC VACCINES MARKET, BY INDICATION, 2021-2031 (REVENUE, $MILLION)

TABLE 44. CANADA GLOBAL PEDIATRIC VACCINES MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)

TABLE 45. CANADA GLOBAL PEDIATRIC VACCINES MARKET, BY TECHNOLOGY, 2021-2031 (REVENUE, $MILLION)

TABLE 46. CANADA GLOBAL PEDIATRIC VACCINES MARKET, BY INDICATION, 2021-2031 (REVENUE, $MILLION)

TABLE 47. MEXICO GLOBAL PEDIATRIC VACCINES MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)

TABLE 48. MEXICO GLOBAL PEDIATRIC VACCINES MARKET, BY TECHNOLOGY, 2021-2031 (REVENUE, $MILLION)

TABLE 49. MEXICO GLOBAL PEDIATRIC VACCINES MARKET, BY INDICATION, 2021-2031 (REVENUE, $MILLION)

TABLE 50. EUROPE GLOBAL PEDIATRIC VACCINES MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)

TABLE 51. EUROPE GLOBAL PEDIATRIC VACCINES MARKET, BY TECHNOLOGY, 2021-2031 (REVENUE, $MILLION)

TABLE 52. EUROPE GLOBAL PEDIATRIC VACCINES MARKET, BY INDICATION, 2021-2031 (REVENUE, $MILLION)

TABLE 53. EUROPE GLOBAL PEDIATRIC VACCINES MARKET, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)

TABLE 54. GERMANY GLOBAL PEDIATRIC VACCINES MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)

TABLE 55. GERMANY GLOBAL PEDIATRIC VACCINES MARKET, BY TECHNOLOGY, 2021-2031 (REVENUE, $MILLION)

TABLE 56. GERMANY GLOBAL PEDIATRIC VACCINES MARKET, BY INDICATION, 2021-2031 (REVENUE, $MILLION)

TABLE 57. FRANCE GLOBAL PEDIATRIC VACCINES MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)

TABLE 58. FRANCE GLOBAL PEDIATRIC VACCINES MARKET, BY TECHNOLOGY, 2021-2031 (REVENUE, $MILLION)

TABLE 59. FRANCE GLOBAL PEDIATRIC VACCINES MARKET, BY INDICATION, 2021-2031 (REVENUE, $MILLION)

TABLE 60. UK GLOBAL PEDIATRIC VACCINES MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)

TABLE 61. UK GLOBAL PEDIATRIC VACCINES MARKET, BY TECHNOLOGY, 2021-2031 (REVENUE, $MILLION)

TABLE 62. UK GLOBAL PEDIATRIC VACCINES MARKET, BY INDICATION, 2021-2031 (REVENUE, $MILLION)

TABLE 63. ITALY GLOBAL PEDIATRIC VACCINES MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)

TABLE 64. ITALY GLOBAL PEDIATRIC VACCINES MARKET, BY TECHNOLOGY, 2021-2031 (REVENUE, $MILLION)

TABLE 65. ITALY GLOBAL PEDIATRIC VACCINES MARKET, BY INDICATION, 2021-2031 (REVENUE, $MILLION)

TABLE 66. SPAIN GLOBAL PEDIATRIC VACCINES MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)

TABLE 67. SPAIN GLOBAL PEDIATRIC VACCINES MARKET, BY TECHNOLOGY, 2021-2031 (REVENUE, $MILLION)

TABLE 68. SPAIN GLOBAL PEDIATRIC VACCINES MARKET, BY INDICATION, 2021-2031 (REVENUE, $MILLION)

TABLE 69. REST OF EUROPE GLOBAL PEDIATRIC VACCINES MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)

TABLE 70. REST OF EUROPE GLOBAL PEDIATRIC VACCINES MARKET, BY TECHNOLOGY, 2021-2031 (REVENUE, $MILLION)

TABLE 71. REST OF EUROPE GLOBAL PEDIATRIC VACCINES MARKET, BY INDICATION, 2021-2031 (REVENUE, $MILLION)

TABLE 72. ASIA-PACIFIC GLOBAL PEDIATRIC VACCINES MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)

TABLE 73. ASIA-PACIFIC GLOBAL PEDIATRIC VACCINES MARKET, BY TECHNOLOGY, 2021-2031 (REVENUE, $MILLION)

TABLE 74. ASIA-PACIFIC GLOBAL PEDIATRIC VACCINES MARKET, BY INDICATION, 2021-2031 (REVENUE, $MILLION)

TABLE 75. ASIA-PACIFIC GLOBAL PEDIATRIC VACCINES MARKET, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)

TABLE 76. CHINA GLOBAL PEDIATRIC VACCINES MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)

TABLE 77. CHINA GLOBAL PEDIATRIC VACCINES MARKET, BY TECHNOLOGY, 2021-2031 (REVENUE, $MILLION)

TABLE 78. CHINA GLOBAL PEDIATRIC VACCINES MARKET, BY INDICATION, 2021-2031 (REVENUE, $MILLION)

TABLE 79. JAPAN GLOBAL PEDIATRIC VACCINES MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)

TABLE 80. JAPAN GLOBAL PEDIATRIC VACCINES MARKET, BY TECHNOLOGY, 2021-2031 (REVENUE, $MILLION)

TABLE 81. JAPAN GLOBAL PEDIATRIC VACCINES MARKET, BY INDICATION, 2021-2031 (REVENUE, $MILLION)

TABLE 82. INDIA GLOBAL PEDIATRIC VACCINES MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)

TABLE 83. INDIA GLOBAL PEDIATRIC VACCINES MARKET, BY TECHNOLOGY, 2021-2031 (REVENUE, $MILLION)

TABLE 84. INDIA GLOBAL PEDIATRIC VACCINES MARKET, BY INDICATION, 2021-2031 (REVENUE, $MILLION)

TABLE 85. AUSTRALIA GLOBAL PEDIATRIC VACCINES MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)

TABLE 86. AUSTRALIA GLOBAL PEDIATRIC VACCINES MARKET, BY TECHNOLOGY, 2021-2031 (REVENUE, $MILLION)

TABLE 87. AUSTRALIA GLOBAL PEDIATRIC VACCINES MARKET, BY INDICATION, 2021-2031 (REVENUE, $MILLION)

TABLE 88. SOUTH KOREA GLOBAL PEDIATRIC VACCINES MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)

TABLE 89. SOUTH KOREA GLOBAL PEDIATRIC VACCINES MARKET, BY TECHNOLOGY, 2021-2031 (REVENUE, $MILLION)

TABLE 90. SOUTH KOREA GLOBAL PEDIATRIC VACCINES MARKET, BY INDICATION, 2021-2031 (REVENUE, $MILLION)

TABLE 91. REST OF ASIA-PACIFIC GLOBAL PEDIATRIC VACCINES MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)

TABLE 92. REST OF ASIA-PACIFIC GLOBAL PEDIATRIC VACCINES MARKET, BY TECHNOLOGY, 2021-2031 (REVENUE, $MILLION)

TABLE 93. REST OF ASIA-PACIFIC GLOBAL PEDIATRIC VACCINES MARKET, BY INDICATION, 2021-2031 (REVENUE, $MILLION)

TABLE 94. LAMEA GLOBAL PEDIATRIC VACCINES MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)

TABLE 95. LAMEA GLOBAL PEDIATRIC VACCINES MARKET, BY TECHNOLOGY, 2021-2031 (REVENUE, $MILLION)

TABLE 96. LAMEA GLOBAL PEDIATRIC VACCINES MARKET, BY INDICATION, 2021-2031 (REVENUE, $MILLION)

TABLE 97. LAMEA GLOBAL PEDIATRIC VACCINES MARKET, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)

TABLE 98. BRAZIL GLOBAL PEDIATRIC VACCINES MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)

TABLE 99. BRAZIL GLOBAL PEDIATRIC VACCINES MARKET, BY TECHNOLOGY, 2021-2031 (REVENUE, $MILLION)

TABLE 100. BRAZIL GLOBAL PEDIATRIC VACCINES MARKET, BY INDICATION, 2021-2031 (REVENUE, $MILLION)

TABLE 101. SAUDI ARABIA GLOBAL PEDIATRIC VACCINES MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)

TABLE 102. SAUDI ARABIA GLOBAL PEDIATRIC VACCINES MARKET, BY TECHNOLOGY, 2021-2031 (REVENUE, $MILLION)

TABLE 103. SAUDI ARABIA GLOBAL PEDIATRIC VACCINES MARKET, BY INDICATION, 2021-2031 (REVENUE, $MILLION)

TABLE 104. SOUTH AFRICA GLOBAL PEDIATRIC VACCINES MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)

TABLE 105. SOUTH AFRICA GLOBAL PEDIATRIC VACCINES MARKET, BY TECHNOLOGY, 2021-2031 (REVENUE, $MILLION)

TABLE 106. SOUTH AFRICA GLOBAL PEDIATRIC VACCINES MARKET, BY INDICATION, 2021-2031 (REVENUE, $MILLION)

TABLE 107. REST OF LAMEA GLOBAL PEDIATRIC VACCINES MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)

TABLE 108. REST OF LAMEA GLOBAL PEDIATRIC VACCINES MARKET, BY TECHNOLOGY, 2021-2031 (REVENUE, $MILLION)

TABLE 109. REST OF LAMEA GLOBAL PEDIATRIC VACCINES MARKET, BY INDICATION, 2021-2031 (REVENUE, $MILLION)

TABLE 110.ASTRAZENECA PLC.: COMPANY SNAPSHOT

TABLE 111.ASTRAZENECA PLC.: OPERATING SEGMENTS

TABLE 112.ASTRAZENECA PLC.: PRODUCT PORTFOLIO

TABLE 113.ASTRAZENECA PLC.: NET SALES

TABLE 114.ASTRAZENECA PLC.: KEY STRATERGIES

TABLE 115.CSL LIMITED: COMPANY SNAPSHOT

TABLE 116.CSL LIMITED: OPERATING SEGMENTS

TABLE 117.CSL LIMITED: PRODUCT PORTFOLIO

TABLE 118.CSL LIMITED: NET SALES

TABLE 119.CSL LIMITED: KEY STRATERGIES

TABLE 120.EMERGENT BIOSOLUTIONS INC.: COMPANY SNAPSHOT

TABLE 121.EMERGENT BIOSOLUTIONS INC.: OPERATING SEGMENTS

TABLE 122.EMERGENT BIOSOLUTIONS INC.: PRODUCT PORTFOLIO

TABLE 123.EMERGENT BIOSOLUTIONS INC.: NET SALES

TABLE 124.EMERGENT BIOSOLUTIONS INC.: KEY STRATERGIES

TABLE 125.GLAXOSMITHKLINE PLC.: COMPANY SNAPSHOT

TABLE 126.GLAXOSMITHKLINE PLC.: OPERATING SEGMENTS

TABLE 127.GLAXOSMITHKLINE PLC.: PRODUCT PORTFOLIO

TABLE 128.GLAXOSMITHKLINE PLC.: NET SALES

TABLE 129.GLAXOSMITHKLINE PLC.: KEY STRATERGIES

TABLE 130.JOHNSON & JOHNSON: COMPANY SNAPSHOT

TABLE 131.JOHNSON & JOHNSON: OPERATING SEGMENTS

TABLE 132.JOHNSON & JOHNSON: PRODUCT PORTFOLIO

TABLE 133.JOHNSON & JOHNSON: NET SALES

TABLE 134.JOHNSON & JOHNSON: KEY STRATERGIES

TABLE 135.MERCK & CO., INC.: COMPANY SNAPSHOT

TABLE 136.MERCK & CO., INC.: OPERATING SEGMENTS

TABLE 137.MERCK & CO., INC.: PRODUCT PORTFOLIO

TABLE 138.MERCK & CO., INC.: NET SALES

TABLE 139.MERCK & CO., INC.: KEY STRATERGIES

TABLE 140.NOVAVAX, INC.: COMPANY SNAPSHOT

TABLE 141.NOVAVAX, INC.: OPERATING SEGMENTS

TABLE 142.NOVAVAX, INC.: PRODUCT PORTFOLIO

TABLE 143.NOVAVAX, INC.: NET SALES

TABLE 144.NOVAVAX, INC.: KEY STRATERGIES

TABLE 145.PFIZER INC.: COMPANY SNAPSHOT

TABLE 146.PFIZER INC.: OPERATING SEGMENTS

TABLE 147.PFIZER INC.: PRODUCT PORTFOLIO

TABLE 148.PFIZER INC.: NET SALES

TABLE 149.PFIZER INC.: KEY STRATERGIES

TABLE 150.SANOFI AVENTIS: COMPANY SNAPSHOT

TABLE 151.SANOFI AVENTIS: OPERATING SEGMENTS

TABLE 152.SANOFI AVENTIS: PRODUCT PORTFOLIO

TABLE 153.SANOFI AVENTIS: NET SALES

TABLE 154.SANOFI AVENTIS: KEY STRATERGIES

TABLE 155.SERUM INSTITUTE OF INDIA PVT. LTD.: COMPANY SNAPSHOT

TABLE 156.SERUM INSTITUTE OF INDIA PVT. LTD.: OPERATING SEGMENTS

TABLE 157.SERUM INSTITUTE OF INDIA PVT. LTD.: PRODUCT PORTFOLIO

TABLE 158.SERUM INSTITUTE OF INDIA PVT. LTD.: NET SALES

TABLE 159.SERUM INSTITUTE OF INDIA PVT. LTD.: KEY STRATERGIES LIST OF FIGURES

FIGURE 1.GLOBAL PEDIATRIC VACCINES MARKET SEGMENTATION

FIGURE 2.GLOBAL PEDIATRIC VACCINES MARKET,2021-2031

FIGURE 3.GLOBAL PEDIATRIC VACCINES MARKET,2021-2031

FIGURE 4. TOP INVESTMENT POCKETS, BY REGION

FIGURE 5.PORTER FIVE-1

FIGURE 6.PORTER FIVE-2

FIGURE 7.PORTER FIVE-3

FIGURE 8.PORTER FIVE-4

FIGURE 9.PORTER FIVE-5

FIGURE 10.TOP PLAYER POSITIONING

FIGURE 11.GLOBAL PEDIATRIC VACCINES MARKET:DRIVERS, RESTRAINTS AND OPPORTUNITIES

FIGURE 12.GLOBAL PEDIATRIC VACCINES MARKET,BY TYPE,2021(%)

FIGURE 13.COMPARATIVE SHARE ANALYSIS OF MONOVALENT GLOBAL PEDIATRIC VACCINES MARKET,2021-2031(%)

FIGURE 14.COMPARATIVE SHARE ANALYSIS OF MULTIVALENT GLOBAL PEDIATRIC VACCINES MARKET,2021-2031(%)

FIGURE 15.GLOBAL PEDIATRIC VACCINES MARKET,BY TECHNOLOGY,2021(%)

FIGURE 16.COMPARATIVE SHARE ANALYSIS OF LIVE ATTENUATED VACCINES GLOBAL PEDIATRIC VACCINES MARKET,2021-2031(%)

FIGURE 17.COMPARATIVE SHARE ANALYSIS OF INACTIVATED VACCINES GLOBAL PEDIATRIC VACCINES MARKET,2021-2031(%)

FIGURE 18.COMPARATIVE SHARE ANALYSIS OF TOXOID VACCINES GLOBAL PEDIATRIC VACCINES MARKET,2021-2031(%)

FIGURE 19.COMPARATIVE SHARE ANALYSIS OF SUBUNIT, RECOMBINANT, POLYSACCHARIDE, AND CONJUGATE VACCINES GLOBAL PEDIATRIC VACCINES MARKET,2021-2031(%)

FIGURE 20.GLOBAL PEDIATRIC VACCINES MARKET,BY INDICATION,2021(%)

FIGURE 21.COMPARATIVE SHARE ANALYSIS OF VARICELLA GLOBAL PEDIATRIC VACCINES MARKET,2021-2031(%)

FIGURE 22.COMPARATIVE SHARE ANALYSIS OF DIPHTHERIA, PERTUSSIS AND TETANUS GLOBAL PEDIATRIC VACCINES MARKET,2021-2031(%)

FIGURE 23.COMPARATIVE SHARE ANALYSIS OF INFLUENZA GLOBAL PEDIATRIC VACCINES MARKET,2021-2031(%)

FIGURE 24.COMPARATIVE SHARE ANALYSIS OF HUMAN PAPILLOMA VIRUS GLOBAL PEDIATRIC VACCINES MARKET,2021-2031(%)

FIGURE 25.COMPARATIVE SHARE ANALYSIS OF MEASLES, MUMPS AND RUBELLA GLOBAL PEDIATRIC VACCINES MARKET,2021-2031(%)

FIGURE 26.COMPARATIVE SHARE ANALYSIS OF MENINGOCOCCAL DISEASE GLOBAL PEDIATRIC VACCINES MARKET,2021-2031(%)

FIGURE 27.COMPARATIVE SHARE ANALYSIS OF PNEUMOCOCCAL DISEASE GLOBAL PEDIATRIC VACCINES MARKET,2021-2031(%)

FIGURE 28.COMPARATIVE SHARE ANALYSIS OF POLIO GLOBAL PEDIATRIC VACCINES MARKET,2021-2031(%)

FIGURE 29.COMPARATIVE SHARE ANALYSIS OF ROTAVIRUS GLOBAL PEDIATRIC VACCINES MARKET,2021-2031(%)

FIGURE 30.COMPARATIVE SHARE ANALYSIS OF OTHER INDICATIONS GLOBAL PEDIATRIC VACCINES MARKET,2021-2031(%)

FIGURE 31.GLOBAL PEDIATRIC VACCINES MARKET BY REGION,2021

FIGURE 32.U.S. GLOBAL PEDIATRIC VACCINES MARKET,2021-2031($MILLION)

FIGURE 33.CANADA GLOBAL PEDIATRIC VACCINES MARKET,2021-2031($MILLION)

FIGURE 34.MEXICO GLOBAL PEDIATRIC VACCINES MARKET,2021-2031($MILLION)

FIGURE 35.GERMANY GLOBAL PEDIATRIC VACCINES MARKET,2021-2031($MILLION)

FIGURE 36.FRANCE GLOBAL PEDIATRIC VACCINES MARKET,2021-2031($MILLION)

FIGURE 37.UK GLOBAL PEDIATRIC VACCINES MARKET,2021-2031($MILLION)

FIGURE 38.ITALY GLOBAL PEDIATRIC VACCINES MARKET,2021-2031($MILLION)

FIGURE 39.SPAIN GLOBAL PEDIATRIC VACCINES MARKET,2021-2031($MILLION)

FIGURE 40.REST OF EUROPE GLOBAL PEDIATRIC VACCINES MARKET,2021-2031($MILLION)

FIGURE 41.CHINA GLOBAL PEDIATRIC VACCINES MARKET,2021-2031($MILLION)

FIGURE 42.JAPAN GLOBAL PEDIATRIC VACCINES MARKET,2021-2031($MILLION)

FIGURE 43.INDIA GLOBAL PEDIATRIC VACCINES MARKET,2021-2031($MILLION)

FIGURE 44.AUSTRALIA GLOBAL PEDIATRIC VACCINES MARKET,2021-2031($MILLION)

FIGURE 45.SOUTH KOREA GLOBAL PEDIATRIC VACCINES MARKET,2021-2031($MILLION)

FIGURE 46.REST OF ASIA-PACIFIC GLOBAL PEDIATRIC VACCINES MARKET,2021-2031($MILLION)

FIGURE 47.BRAZIL GLOBAL PEDIATRIC VACCINES MARKET,2021-2031($MILLION)

FIGURE 48.SAUDI ARABIA GLOBAL PEDIATRIC VACCINES MARKET,2021-2031($MILLION)

FIGURE 49.SOUTH AFRICA GLOBAL PEDIATRIC VACCINES MARKET,2021-2031($MILLION)

FIGURE 50.REST OF LAMEA GLOBAL PEDIATRIC VACCINES MARKET,2021-2031($MILLION)

FIGURE 51. TOP WINNING STRATEGIES, BY YEAR

FIGURE 52. TOP WINNING STRATEGIES, BY DEVELOPMENT

FIGURE 53. TOP WINNING STRATEGIES, BY COMPANY

FIGURE 54.PRODUCT MAPPING OF TOP 10 PLAYERS

FIGURE 55.COMPETITIVE DASHBOARD

FIGURE 56.COMPETITIVE HEATMAP OF TOP 10 KEY PLAYERS

FIGURE 57.ASTRAZENECA PLC..: NET SALES ($MILLION)

FIGURE 58.CSL LIMITED.: NET SALES ($MILLION)

FIGURE 59.EMERGENT BIOSOLUTIONS INC..: NET SALES ($MILLION)

FIGURE 60.GLAXOSMITHKLINE PLC..: NET SALES ($MILLION)

FIGURE 61.JOHNSON & JOHNSON.: NET SALES ($MILLION)

FIGURE 62.MERCK & CO., INC..: NET SALES ($MILLION)

FIGURE 63.NOVAVAX, INC..: NET SALES ($MILLION)

FIGURE 64.PFIZER INC..: NET SALES ($MILLION)

FIGURE 65.SANOFI AVENTIS.: NET SALES ($MILLION)

FIGURE 66.SERUM INSTITUTE OF INDIA PVT. LTD..: NET SALES ($MILLION